SUBSCRIBE
SUBSCRIBE

BioSpace Insights

The BioSpace Insights team performs research and analysis on industry trends for BioSpace and clients, producing industry reports, podcasts, events and articles.

Insights
From Sound Bites to Signals: Editors Parse Executive and Investor Chatter at JPM
In this episode of Denatured, BioSpace editorial team members, Senior Editor, Annalee Armstrong, and News Editor, Dan Samorodnitsky, discuss their post-JPM takeaways and 2026 forecasts after speaking to a range of pharma and biotech executives and investors last week.
January 22, 2026
 · 
1 min read
 · 
Jennifer Smith-Parker
MRI or magnetic resonance imaging of the head and brain. Close up
Insights
The New Gold Rush in Brain Science
Fueled by advances in biomarkers, brain mapping, and AI, investment in neuro and CNS innovation shows no signs of slowing, even amid costly setbacks. BioSpace spoke to investors at JPM26 to get their take on recent bets in new therapies and neurotech.
January 22, 2026
 · 
5 min read
 · 
Jennifer Smith-Parker
IN PARTNERSHIP WITH LOTTE BIOLOGICS
LOTTE Biologics Tightens Global Quality as Syracuse ADC Hub Ramps for 2026
With inspections always on the table, LOTTE Biologics is pushing a proactive, quality first culture across its dual hubs in Syracuse and Songdo, backing its new single‑use ADC facility with rigorous training, self‑audits and real‑time regulatory surveillance.
January 19, 2026
 · 
2 min read
 · 
Jennifer Smith-Parker
Job Trends
Report: U.S. Life Sciences Job Market Report Q4 2025
BioSpace’s 2025 Q4 U.S. Life Sciences Job Market update highlights early signs of stabilization in biopharma hiring, with modest gains in job postings, slowing layoffs, and cautiously improving sentiment heading into 2026.
January 19, 2026
 · 
1 min read
 · 
BioSpace Insights
Inspect the property. Businessman boss using a magnifying glass to look at piles of money. vector
Insights
JPM26: As Capital Concentrates, VCs Scrutinize Founder Pedigree and CEO Fit in Early Biotech
Venture funds attending the J.P. Morgan Healthcare Conference said mounting funding pressures and Chinese competition have sharpened their focus on leadership qualities, from regulatory expertise and industry experience to the ability to scale—or step aside—as companies mature.
January 15, 2026
 · 
2 min read
 · 
Jennifer Smith-Parker
Insights
From Nuclear Winter to Renewal: Biotech Investing for 2026
In this episode of Denatured, Jennifer C. Smith-Parker speaks to Maha Katabi, general partner at Sofinnova Investments and Andrew Lam, managing director, head of Biotech Private Equity at Ally Bridge Group, about how M &A dynamics, dealmaking and global partnerships are reshaping portfolio valuations and paths to growth in 2026.
January 8, 2026
 · 
1 min read
 · 
Jennifer Smith-Parker
Two individuals shake hands in front of advanced laboratory equipment, symbolizing a partnership or agreement in the pharmaceutical industry.
Insights
Biotech Investors Bet on a 2026 Rebound as Deal Activity Accelerates
After a prolonged funding chill, investors say 2026 is shaping up for continued dealmaking and diversified bets beyond oncology and immunology.
January 7, 2026
 · 
3 min read
 · 
Jennifer Smith-Parker
A female doctor of mixed race, meets with a senior couple as she reviews recent test results with them. The senior couple of African decent, listens closely as they receive the good news.
IN PARTNERSHIP WITH TAKEDA
Takeda’s Commitment to Trial Representation is Shaping the Future of Clinical Research
One way Takeda lives out its values is by striving to ensure that patients are aware of and can access the company’s clinical trials. Two employees from its research and development organization discuss why representation matters and the work their team is doing to benefit patients now and in the future.
January 5, 2026
 · 
5 min read
 · 
BioSpace Insights
Deals
Inside the 2026 Biotech Landscape: Innovation, Investment and Global Momentum
In this episode of Denatured, Jennifer Smith-Parker speaks to Kenneth Galbraith, ⁠CEO of Zymeworks and Josh Smiley, president and COO of Zai Lab, about how renewed confidence is driving biotech entering 2026.
December 18, 2025
 · 
1 min read
 · 
BioSpace Insights
China High Resolution Innovation Concept
Insights
Uptick in Dealmaking, Chinese Partnerships Drive Biotech’s Comeback
Biotech’s slump may finally be over in 2026. In interviews with BioSpace, Zymeworks’ CEO Ken Galbraith and Zai Lab’s President and COO Josh Smiley explain what’s fueling the comeback.
December 17, 2025
 · 
3 min read
 · 
Jennifer Smith-Parker
IN PARTNERSHIP WITH ANAPTYSBIO
Beyond the Gluten-Free Diet: A New Era in Celiac Disease Treatment
In this episode of Denatured presented by AnaptysBio, Jennifer Smith-Parker speaks to Dr. Joe Murray, Mayo Clinic; Marilyn Geller, the Celiac Disease Foundation; and Dr. Paul Lizzul, AnaptysBio, about the challenges and opportunities facing celiac disease treatment.
December 11, 2025
 · 
1 min read
 · 
Jennifer Smith-Parker
Hands, tablet and doctor with body hologram, overlay and dna research for medical innovation on app. Medic man, nurse and mobile touchscreen for typing on anatomy study or 3d holographic ux in clinic
Insights
As FDA Deploys Agentic AI, Pharma Begins Testing the Next Frontier of Intelligent Automation
The agency’s sweeping rollout and staff challenge underscore rising momentum behind agentic AI: advanced, multiagent systems now fueling early pilots in medical writing, patient engagement and regulatory workflows across the industry.
December 8, 2025
 · 
3 min read
 · 
Jennifer Smith-Parker
In partnership with PII
Bridging Formulation and Device: Integrated Supply Chain Strategies for U.S. Pharma Manufacturing
The pharmaceutical supply chain and device development have become intricately linked. Harmonizing formulation development with drug delivery device design—and leveraging a single‐vendor ecosystem—can deliver significant time, cost, and regulatory advantages for US‑focused drug products, according to industry experts.

December 8, 2025
 · 
5 min read
 · 
Jennifer Smith-Parker
FDA
New Approach Methodologies: Redefining Animal Testing Alternatives
In this episode of Denatured, Jennifer C. Smith-Parker speaks to Stacey Adam, PhD, Vice President of Science Partnerships at the Foundation for the National Institutes of Health and Patrick Smith, Senior Vice President, Translational Science at Certara, to discuss the latest regulatory news and the future for new approach methologies (NAMs) development.
December 4, 2025
 · 
1 min read
 · 
BioSpace Insights
Hand turns dice and changes the expression 'know the rules'. to 'follow the rules'.
Insights
New UK/EU Rules and AI Adoption Define CRO Priorities for 2026
With new UK clinical trial rules landing in 2026, the EU Biotech Act on the horizon and China and Australia gaining ground, CROs are zeroing in on study timelines, AI/ML and data privacy as the industry’s next pressure points.
December 3, 2025
 · 
4 min read
 · 
Jennifer Smith-Parker
Load More